Cannabis Science Inc (OTCMKTS:CBIS) has joined forces with IBX Bio Inc. for an FDA accepted clinical trial. The trial will research the use of the combination of CS-TATI-1 and GenePro®.

The details

CS-TATI-1 is a cannabinoid based drug whereas GenePro® is the lead product of the biotechnology firm IBX Bio Inc. The later firm has formulated DNA constructs of non-infectious HIV which they believe will result antibodies. The collaboration between the two firms is historic, increasing the synergistic effects of advanced HIV immunotherapy and cannabinoids.

The extensive research highlights that effects of CBDs reduces inflammation and also blocks HIV replication. Both the things are correlated with each other as HIV causes inflammation, even when it is at low levels. Cannabis Science believes CBDs are the ‘missing puzzle piece’ to complete picture of GenePro®.

The expert comments

Mr. Raymond C. Dabne, the President of Cannabis Science states that the alliance with IGX Bio is planned to help offer new insights into the function of inflammation and healing vaccination of HIV as a vital step for getting effective treatments for AIDS patients in different resource settings.

These trials will offer a scientific evaluation of CS-TATI-1 and GenePro® to show the increased potential of the anti-inflammatory effects of CBDs and therapeutic vaccination to deter disease growth in AID patients unable to reach control HIV replication. The company is currently focusing on lead drug CS-TATI-1 along with two other drugs.

The expectations

IBX states only GenePro® stimulates an antibody as well as a cellular response in HIV patients. The drug CS-TATI-1 is not planned to buffer the impact of the drug, but it is aimed to systematically destruct HIV copies concurrently with GenePro®. The plan is to slow down HIV without harsh side effects.

Previous articleNanoTech Entertainment, Inc. (OTCMKTS:NTEK) Acquires
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.